États-Unis · Agences & temps réel · Business Wire

Ropeg Gains ET Approvals in Major Global Markets as European Patients Await Access

Publié par Business Wire · États-Unis il y a 13 h

PharmaEssentia’s blood cancer treatment, ropeginterferon alfa-2b (Ropeg), has secured approvals for essential thrombocythemia (ET) in Taiwan, Japan, the ...

Lire l'article complet sur Business Wire Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.businesswire.com)

Ropeg Gains ET Approvals in Major Global Markets as European Patients Await Access

À lire aussi

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lumentum Holdings Inc. (NASDAQ: LITE)

8 innovative gifts meant to change up how we drive, cook, sleep and more

Rethinking AI in Enterprise Intelligence

Global Financial News from MT Newswires Now Live in Microsoft Copilot

Ropeg Gains ET Approvals in Major Global Markets as European Patients Await Access

Partager

À lire aussi

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lumentum Holdings Inc. (NASDAQ: LITE)

8 innovative gifts meant to change up how we drive, cook, sleep and more

Rethinking AI in Enterprise Intelligence

Global Financial News from MT Newswires Now Live in Microsoft Copilot